Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableBusiness Wire • 06/20/24
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseBusiness Wire • 06/13/24
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare ConferenceBusiness Wire • 05/29/24
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 05/14/24
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseBusiness Wire • 05/08/24
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayBusiness Wire • 04/25/24
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 04/22/24
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseBusiness Wire • 03/28/24
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVieSeeking Alpha • 03/24/24
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceBusiness Wire • 02/06/24
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's ProspectsSeeking Alpha • 01/28/24
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesBusiness Wire • 01/04/24
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisBusiness Wire • 12/19/23
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisBusiness Wire • 12/18/23
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseBusiness Wire • 11/27/23